122 related articles for article (PubMed ID: 32944848)
1. Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer.
Pimenta JR; Racy DJ; Zapata LM; D'Alpino Peixoto R
J Gastrointest Cancer; 2021 Jun; 52(2):784-787. PubMed ID: 32944848
[No Abstract] [Full Text] [Related]
2. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
Grothey A
Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
[No Abstract] [Full Text] [Related]
3. Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.
Rosati G; Del Gaudio N; Scarano E; Cifarelli RA; Altucci L; Bilancia D
Medicine (Baltimore); 2018 Jun; 97(25):e11178. PubMed ID: 29924031
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib in metastatic colorectal cancer.
Grothey A
Clin Adv Hematol Oncol; 2012 May; 10(5):324-5. PubMed ID: 22706543
[No Abstract] [Full Text] [Related]
6. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
7. [Seven Cases of Metastatic Colorectal Cancer Treated with Dose-Reduced and Duration-Reduced Regorafenib Treatment].
Nakashima M; Fujiwara H; Nakao E; Maebashi M; Sugimasa N; Kakizoe M; Ono H; Sugita M
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1673-1676. PubMed ID: 30449862
[TBL] [Abstract][Full Text] [Related]
8. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib Treatment for Management of Colorectal Cancer: A Systematic Review and Meta-analysis of 6 Randomized Controlled Trials.
Wang Y; Liu S; Liu S; Li X; Liu Q; Zou X; Zhu M; Jiang Y
Am J Ther; 2018; 25(2):e276-e278. PubMed ID: 28938279
[No Abstract] [Full Text] [Related]
10. How translational research can guide the use of regorafenib in patients with metastatic colorectal cancer.
Prager GW
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):18-21. PubMed ID: 33843907
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies.
Draper A
Oncology (Williston Park); 2019 Apr; 33(4):126-7. PubMed ID: 30990563
[No Abstract] [Full Text] [Related]
13. Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer.
Grothey A; Bekaii-Saab TS; Yoshino T; Prager GW
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):1-24. PubMed ID: 33843903
[TBL] [Abstract][Full Text] [Related]
14. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
[TBL] [Abstract][Full Text] [Related]
15. Cases in the management of metastatic colorectal cancer: use of regorafenib as a bridge to chemotherapy.
Marshall JL
Clin Adv Hematol Oncol; 2021 Feb; 19 Suppl 6(2):1-8. PubMed ID: 33843886
[No Abstract] [Full Text] [Related]
16. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
[TBL] [Abstract][Full Text] [Related]
17. The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong.
Lam KO; Lee KC; Chiu J; Lee VH; Leung R; Choy TS; Yau T
Postgrad Med J; 2017 Jul; 93(1101):395-400. PubMed ID: 27836933
[TBL] [Abstract][Full Text] [Related]
18. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
Oncology (Williston Park); 2012 Oct; 26(10):896. PubMed ID: 23175993
[No Abstract] [Full Text] [Related]
19. [Multikinase inhibitor regorafenib offers an efficient therapeutic alternative].
Rev Med Suisse; 2014 May; 10(431):1108. PubMed ID: 24941678
[No Abstract] [Full Text] [Related]
20. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study.
Kim JH; Kim SY; Kim KP; Kim TW; Chae SY; Kim HJ; Kim JS; Ryu JS; Moon DH; Kim JE; Hong YS
Target Oncol; 2019 Dec; 14(6):689-697. PubMed ID: 31555963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
